Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus.

Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug-resistant (MDR) bacterial pathogen of acute clinical significance. Resistance to current standard-of-care antibiotics, such as vancomycin and linezolid, among nosocomial and community-acquired MRSA clinical isolates is on the rise. This threat to global public health highlights the need to develop new antibiotics for the treatment of MRSA infections. Here, we describe a new benzamide FtsZ inhibitor (TXH9179) with superior antistaphylococcal activity relative to earlier-generation benzamides like PC190723 and TXA707. TXH9179 was found to be 4-fold more potent than TXA707 against a library of 55 methicillin-sensitive S. aureus (MSSA) and MRSA clinical isolates, including MRSA isolates resistant to vancomycin and linezolid. TXH9179 was also associated with a lower frequency of resistance relative to TXA707 in all but one of the MSSA and MRSA isolates examined, with the observed resistance being due to mutations in the ftsZ gene. TXH9179 induced changes in MRSA cell morphology, cell division, and FtsZ localization are fully consistent with its actions as a FtsZ inhibitor. Crystallographic studies demonstrate the direct interaction of TXH9179 with S. aureus FtsZ (SaFtsZ), while delineating the key molecular contacts that drive complex formation. TXH9179 was not associated with any mammalian cytotoxicity, even at a concentration 10-fold greater than that producing antistaphylococcal activity. In serum, the carboxamide prodrug of TXH9179 (TXH1033) is rapidly hydrolyzed to TXH9179 by serum acetylcholinesterases. Significantly, both intravenously and orally administered TXH1033 exhibited enhanced in vivo efficacy relative to the carboxamide prodrug of TXA707 (TXA709) in treating a mouse model of systemic (peritonitis) MRSA infection. Viewed as a whole, our results highlight TXH9179 as a promising new benzamide FtsZ inhibitor worthy of further development.

[1]  E. LaVoie,et al.  Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant Staphylococcus aureus , 2022, Medicinal Chemistry Research.

[2]  Tao Zhang,et al.  Design, synthesis and biological evaluation of biphenyl-benzamides as potent FtsZ inhibitors. , 2022, European journal of medicinal chemistry.

[3]  Ling Yang,et al.  Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review. , 2021, Microbial pathogenesis.

[4]  P. Sass,et al.  Cell division protein FtsZ: from structure and mechanism to antibiotic target. , 2020, Future microbiology.

[5]  E. LaVoie,et al.  Structure-Guided Design of a Fluorescent Probe for the Visualization of FtsZ in Clinically Important Gram-Positive and Gram-Negative Bacterial Pathogens , 2019, Scientific Reports.

[6]  S. Harbarth,et al.  Methicillin-resistant Staphylococcus aureus , 2018, Nature Reviews Disease Primers.

[7]  H. Fan,et al.  Identification of a strong and specific antichlamydial N-acylhydrazone , 2017, PloS one.

[8]  E. LaVoie,et al.  Structural Flexibility of an Inhibitor Overcomes Drug Resistance Mutations in Staphylococcus aureus FtsZ. , 2017, ACS chemical biology.

[9]  M. Pallavicini,et al.  3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell division. , 2016, European journal of medicinal chemistry.

[10]  S. Peacock,et al.  Mechanisms of Methicillin Resistance in Staphylococcus aureus. , 2015, Annual review of biochemistry.

[11]  M. Pallavicini,et al.  Benzodioxane-benzamides as new bacterial cell division inhibitors. , 2015, European journal of medicinal chemistry.

[12]  D. Davies,et al.  Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ. , 2014, Bioorganic & medicinal chemistry letters.

[13]  E. LaVoie,et al.  Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. , 2013, Biochemical pharmacology.

[14]  Sujata Sharma,et al.  Mechanism of action of the cell-division inhibitor PC190723: modulation of FtsZ assembly cooperativity. , 2012, Journal of the American Chemical Society.

[15]  Eric Langlois,et al.  Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics , 2012, Science Translational Medicine.

[16]  Jeff Errington,et al.  Bacterial cell division: assembly, maintenance and disassembly of the Z ring , 2009, Nature Reviews Microbiology.

[17]  Ian Collins,et al.  An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity , 2008, Science.

[18]  W. Margolin,et al.  FtsZ and the division of prokaryotic cells and organelles , 2005, Nature Reviews Molecular Cell Biology.

[19]  Philippe Moreillon,et al.  Beta-lactams against methicillin-resistant Staphylococcus aureus. , 2005, Current opinion in pharmacology.

[20]  J. Errington,et al.  Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery , 2003, Molecular microbiology.